1315 CAPITAL
1315 CAPITAL is a Series C+ and buyout fund in the US writing $20M–$50M checks into healthcare-services, pharma-medtech-products, pharma-medtech-outsourcing and health-and-wellness.
- Stages
- Series C+, buyout
- Sectors
- healthcare-services, pharma-medtech-products, pharma-medtech-outsourcing, health-and-wellness
- Check size
- $20M–$50M
- Invests in
- US-wide
- Actively investing
- Yes
- Founded
- 2014
- Assets under management
- $1B+
- Website
- 1315capital.com
Thesis
Their investment thesis centers on partnering with commercial-stage businesses in healthcare services, pharma/medtech products, pharma/medtech outsourcing, and health & wellness. They provide expansion and growth capital, focusing on companies with significant revenue potential (targeting $50M-$200M) and those that can benefit from hands-on operational support. The firm engages in both minority and majority investments, often through proprietary deal sourcing. With over $1 billion in AUM, recent fundraising includes over $500 million combined for 1315 Capital III and Emerging Growth and Buyout (EGB) in October 2023. Future funds like 1315 Capital IV and EGB II are targeting larger enterprise values and specific revenue thresholds, with equity checks ranging from $15 million to $50+ million. They primarily invest in North America, focusing on commercial-stage companies beyond early startup phases, aiming to build scalable businesses that improve patient outcomes and the healthcare system.
Common questions
Does 1315 CAPITAL invest at the Series C+ stage?
Yes. 1315 CAPITAL lists Series C+ and buyout among the stages it invests in.
What check size does 1315 CAPITAL write?
1315 CAPITAL writes $20M–$50M checks.
Where does 1315 CAPITAL invest?
1315 CAPITAL invests in the US.